Longevity Health Faces Competition in Surgical Supplies Market

Longevity Health's institutional and insider ownership, stock volatility, and financial metrics compared to industry peers.

Published on Feb. 25, 2026

Got story updates? Submit your updates here. ›

A critical comparison of Longevity Health (XAGE), a medical device company, and its competitors in the 'Surgical, Medical, And Dental Instruments And Supplies' industry. The analysis looks at institutional and insider ownership, stock volatility, profit margins, return on equity, and other key financial metrics to assess Longevity Health's competitive position.

Why it matters

This analysis provides investors with a comprehensive view of Longevity Health's strengths and weaknesses relative to its industry peers. It highlights areas where the company may have an advantage, as well as areas where it lags behind the competition. This information is crucial for investors to make informed decisions about the company's long-term growth potential.

The details

Longevity Health has 24.2% institutional ownership, compared to 22.5% for its industry peers. The company also has a higher insider ownership at 29.0%, versus 18.4% for competitors. Longevity Health's stock is also less volatile, with a beta of 0.38 compared to 1.76 for its peers. In terms of financial metrics, Longevity Health has higher net margins, return on equity, and return on assets than its competitors, despite having lower revenue.

  • The analysis is based on data as of February 25, 2026.

The players

Longevity Health

A medical device company focused on developing products for tissue repair and growth.

Carmell Therapeutics Corporation

A company that develops plasma-based bioactive materials to stimulate tissue repair and growth, with a focus on bone healing and chronic wound healing.

Got photos? Submit your photos here. ›

The takeaway

Longevity Health appears to have some competitive advantages over its peers, including stronger institutional and insider ownership, lower stock volatility, and better financial metrics. However, the company still faces stiff competition in the surgical supplies market, and investors should closely monitor its performance and strategy relative to its competitors.